••••••

.

• • • • • • • • • • • • • • • • • • •

•••••

• • • • • • • • • • • • • • • • • •

............

BACKGROUND

- Patients with severe asthma often need treatment with biologics through the specialty pharmacy.
- The Asthma Control Test (ACT) is a validated measure to identify uncontrolled asthma and evaluate treatment progress.
- The trajectory of ACT scores over time may depend on factors commonly evaluated within specialty pharmacies like adherence, symptom triggers, and comorbidities.
- Deciphering the interplay among elements related to symptom improvement may aid specialty pharmacies in designing targeted initiatives to improve asthma care.

OBJECTIVE

To evaluate ACT score trajectories and determine factors related to asthma improvement among asthma patients treated within the specialty pharmacy.

METHODS

Inclusion:

Patients ≥12-years-old with asthma who had:

- 1+ medications dispensed in 2023 from our specialty pharmacy.
- Both a Baseline ACT (first ACT in 2023) and ≥1 ACT score reported 30-365 days following Baseline.

ACT scores:

 Categorized as Very Poorly (<16 points), Not Well (16-19 points), or Well Controlled (20-25 points).

Analysis:

- Characteristics were compared across ACT groups and whether minimally important difference¹ (MID; ≥3 point improvement) was met using chi-squared tests.
- Logistic regressions estimated odds of asthma improvement.

Fairview

AC[°] Cat

Trajectory of Asthma Control Test (ACT) Scores **Among Patients Treated Within the Specialty Pharmacy**

Alicia Zagel, PhD, MPH; Marjorie Wittenborg, BS Pharm; Sandra III, PharmD; Ann McNamara, PharmD Fairview Pharmacy Services, Minneapolis, MN

RESULTS

TABLE 1: Baseline Population Characteristics

		Very Poorly Controlled	:	Well Controlled	Total	p- value	
Total Population		63 (55.3)	18 (15.8)	33 (28.9)	114 (100.0)		
Age, yrs; m	edian (IQR)	51 (37, 60)	51 (40, 56)	54 (42, 62)	52 (40, 60)	0.30	
Nasal Polyps		5 (7.9)	3 (16.67)	7 (21.2)	15 (13.2)	0.17	
Atopic Dermatitis		4 (6.34	1 (5.56)	1 (3.0)	6 (5.3)	0.79	
Insurance	Commercial	25 (39.7)	9 (50.0)	16 (48.5)	50 (43.9)		
	Medicaid	33 (52.4)	9 (50.0)	12 (36.4)	54 (47.4)		
	Medicare	5 (7.9)	0 (0.0)	5 (15.2)	10 (8.8)	0.29	
Asthma Triggers	Animals	5 (7.9)	2 (11.11)	6 (18.2)	13 (11.4)	0.32	
	Cold Air	13 (20.6)	5 (27.78)	4 (12.1)	22 (19.3)	0.37	
	Dust Mites	5 (7.9)	5 (27.78)	7 (21.2)	17 (14.9)	0.06	
	Exercise	19 (30.2)	4 (22.22)	8 (24.2)	31 (27.2)	0.73	
	Humidity	12 (19.1)	3 (16.67)	4 (12.1)	19 (16.7)	0.69	
	Mold	3 (4.8)	3 (16.67)	5 (15.2)	11 (9.6)	0.14	
	Pollens	10 (15.9)	5 (27.78)	13 (39.4)	28 (24.6)	0.037	
	Smoke	11 (17.5)	6 (33.33)	4 (12.1)	21 (18.4)	0.17	
	Odors/Fumes	6 (9.5)	1 (5.56)	5 (15.2)	12 (10.5)	0.52	
	URI	15 (23.8)	5 (27.78)	7 (21.2)	27 (23.7)	0.87	
	Other	31 (49.2)	6 (33.33)	15 (45.5)	52 (45.6)	0.49	
Therapy Type	Current	17 (27.0)	10 (55.56)	24 (72.7)	51 (44.7)		
	New	46 (73.0)	8 (44.44)	9 (27.3)	63 (55.3)	<.0001	
Follow-up ACT Score; median (IQR)		16 (12, 20)	20 (19, 22)	23 (22, 25)	19 (15, 23)	<.0001	
Change in ACT; median (IQR)		4 (0, 9)	3.5 (1, 6)	0 (-2, 1)	2 (0, 6)	<.0001	

At Baseline (Table 1):


- Insurance, age, comorbid diagnoses, and asthma triggers were distributed similarly by Baseline ACT score category.
- Patients who were Very **Poorly Controlled** at baseline
- Were more likely to be new to therapy (p<.0001)
- Had a median improvement of 4 points
- 25% improved >9 points
- Patients who were Not Well Controlled had a median improvement of 3.5 points


FIGURE 2: Adjusted Odds and 95% Confidence Intervals of Being Well Controlled and Meeting MID at Follow-up

Ou ^r Basel
ACT:
\geq
Ou
Basel
ACT:
Ou
Basel ACT:

TABLE 2: Follow-up ACT and MID Categories by Care Characteristics

			Follow-Up	Follow-Up ACT Score Category			Met MID			
		Total	Very Poorly Controlled	Not Well Controlled	Well Controlled	p-value	No	Yes	p-value	
	Total Population	114 (100.0)	32 (28.1)	26 (22.8)	56 (49.1)		62 (54.4)	52 (45.6)		At Follo
seline	Very Poorly Controlled	63 (55.3)	29 (90.6)	18 (69.2)	16 (28.6)		23 (37.1)	40 (76.9)		Base
CT Score	Not Well Controlled	18 (15.8)	1 (3.1)	5 (19.2)	12 (21.4)		8 (12.9)	10 (19.2)		categ
tegory	Well Controlled	33 (28.9)	2 (6.3)	3 (11.5)	28 (50.0)	<.0001	31 (50.0)	2 (3.8)	<.0001	assoc
dyear M	ed Switch	9 (7.89)	4 (12.5)	3 (11.5)	2 (3.6)	0.24	6 (9.7)	3 (5.8)	0.51	ACT
	Missing	5 (4.4)	0 (0.0)	0 (0.00)	5 (8.9)		2 (3.2)	3 (5.8)		meeti
lherent	No	21 (18.4)	10 (31.3)	6 (23.1)	5 (8.9)		12 (19.4)	9 (17.3)		 Patier Control
	Yes	88 (77.2)	22 (68.8)	20 (76.9)	46 (82.1)	0.021	48 (77.4)	40 (76.9)	0.79	Contr were
erapy	Current	51 (44.7)	14 (43.8)	7 (26.9)	30 (53.6)		36 (58.1)	15 (28.8)		adhei
ре	New	63 (55.3)	18 (56.3)	19 (73.1)	26 (46.4)	0.077	26 (41.9)	37 (71.2)	0.0018	 Patier
	Commercial	50 (43.9)	6 (18.8)	12 (46.2)	32 (57.1)		21 (33.9)	29 (55.8)		insur
surance	Medicaid	54 (47.4)	22 (68.8)	13 (50.0)	19 (33.9)		32 (51.6)	22 (42.3)		likely
	Medicare	10 (8.8)	4 (12.5)	1 (3.8)	5 (8.9)	0.0096	9 (14.5)	1 (1.9)	0.013	Contr





DISCUSSION

- score category (Table 1).

- insurance (data not shown).
- follow-up (Figure 2).

CONCLUSION

- up within the specialty pharmacy.
- MID and remain adherent.
- specialty pharmacy
- outcomes.
- assessments may be important.

REFERENCES

Schatz M, Kosinski M, Yarlas AS, Hanlon J, Watson ME, Jhingran P. The minimally important difference of the Asthma Control Test. J Allergy Clin Immunol. 2009 Oct;124(4):719-23.e1. doi: 10.1016/j.jaci.2009.06.053. Epub 2009 Sep 19. PMID: 19767070.USP (United States Pharmacopia): "USP General Chapter <800> Hazardous Drugs—Handling in Healthcare Settings" Available at http://www.usp.org/compoundig/general-chapter-hazardous-drugs-handling-healthcare (2018)

• • • • • • • • • • • • • • • • •

Insurance was not significantly associated with Baseline ACT

However, it was significantly associated with Follow-up ACT score category and whether a patient met MID (Table 2).

Insurance type was associated with adherence (p=0.0007).

18 of 21 (85.7%) patients with PDC < 0.8 were on Medicaid</p>

Even after adjusting for baseline ACT category, certain triggers (like odors/fumes), adherence, and insurance type are

associated with being well-controlled and/or meeting MID at

Most asthma patients were Well Controlled or met MID at Follow-

• Patients with commercial insurance were most likely to achieve

 Goals for asthma control are often either set as meeting the MID or being Well Controlled; understanding factors related to ACT trajectories may aid in personalizing care goals for patients in the

Other studies indicate that patients experiencing greater social determinants of health are at higher risk of poorer asthma

> Incorporating insurance, nonadherence, triggers, and ACT score trajectories into counseling and frequency of pharmacy

 Additional analysis of the reasons for poor ACT score trajectories may help identify opportunities for further collaborative care.

• • • • • • • • • • • • • • • • •